Bicara Therapeutics (BCAX) EBITDA (2023 - 2026)

Bicara Therapeutics' EBITDA history runs 4 years deep, the most recent figure standing at -$60.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 44.16% year-over-year to -$60.2 million; the TTM figure through Mar 2026 stood at -$174.1 million (down 59.98% YoY), while the FY2025 annual figure was -$155.6 million, down 88.87% from the prior year.
• EBITDA for Q1 2026 stood at -$60.2 million, down from -$41.1 million in the prior quarter.
• The five-year high for EBITDA was -$9.5 million in Q3 2023, with the low at -$60.2 million in Q1 2026.
• The 4-year median for EBITDA is -$26.6 million (2024), against an average of -$29.2 million.
• The sharpest annual moves came in 2025 and 2026: EBITDA tumbled 171.81% in 2025, then slumped 44.16% in 2026.
• Bicara Therapeutics' EBITDA stood at -$13.7 million in 2023, then tumbled by 94.62% to -$26.6 million in 2024, then sank by 54.38% to -$41.1 million in 2025, then plunged by 46.5% to -$60.2 million in 2026.
• Business Quant data shows BCAX's EBITDA at -$60.2 million in Q1 2026, -$41.1 million in Q4 2025, and -$40.7 million in Q3 2025.